Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention

Abankwa D, Gorfe AA, Inder K, Hancock JF (2010) Ras membrane orientation and nanodomain localization generate isoform diversity. Proc Natl Acad Sci U S A 107:1130–1135. https://doi.org/10.1073/pnas.0903907107 Abdul-Manan N, Aghazadeh B, Liu GA, Majumdar A, Ouerfelli O, Siminovitch KA, Rosen MK (1999) Structure of Cdc42 in complex with the GTPase-binding domain of the ‘Wiskott-Aldrich syndrome’ protein. Nature 399:379–383. https://doi.org/10.1038/20726 Abraham D et al (2000) Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem 275:22300–22304. https://doi.org/10.1074/jbc.M003259200 Abraham SJ, Nolet RP, Calvert RJ, Anderson LM, Gaponenko V (2009) The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin. Biochemistry 48:7575–7583. https://doi.org/10.1021/bi900769j Agamasu C, Ghanam RH, Saad JS (2015) Structural and biophysical characterization of the interactions between calmodulin and the pleckstrin homology domain of Akt. J Biol Chem 290:27403–27413. https://doi.org/10.1074/jbc.M115.673939 Agamasu C, Ghanam RH, Xu F, Sun Y, Chen Y, Saad JS (2017) The interplay between calmodulin and membrane interactions with the pleckstrin homology domain of Akt. J Biol Chem 292:251–263. https://doi.org/10.1074/jbc.M116.752816 Ahearn IM, Haigis K, Bar-Sagi D, Philips MR (2011) Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol 13:39–51. https://doi.org/10.1038/nrm3255 Alvarez-Moya B, Barcelo C, Tebar F, Jaumot M, Agell N (2011) CaM interaction and Ser181 phosphorylation as new K-Ras signaling modulators. Small GTPases 2:99–103. https://doi.org/10.4161/sgtp.2.2.15555 Artim SC, Mendrola JM, Lemmon MA (2012) Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family. Biochem J 448:213–220. https://doi.org/10.1042/BJ20121365 Atcheson E, Hamilton E, Pathmanathan S, Greer B, Harriott P, Timson DJ (2011) IQ-motif selectivity in human IQGAP2 and IQGAP3: binding of calmodulin and myosin essential light chain. Biosci Rep 31:371–379. https://doi.org/10.1042/BSR20100123 Avruch J, Xavier R, Bardeesy N, Zhang XF, Praskova M, Zhou D, Xia F (2009) Rassf family of tumor suppressor polypeptides. J Biol Chem 284:11001–11005. https://doi.org/10.1074/jbc.R800073200 Avruch J, Zhou D, Fitamant J, Bardeesy N, Mou F, Barrufet LR (2012) Protein kinases of the Hippo pathway: regulation and substrates. Semin Cell Dev Biol 23:770–784. https://doi.org/10.1016/j.semcdb.2012.07.002 Backer JM et al (1992) Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J 11:3469–3479 Banerjee A, Jang H, Nussinov R, Gaponenko V (2016) The disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding. Curr Opin Struct Biol 36:10–17. https://doi.org/10.1016/j.sbi.2015.11.010 Barnoud T, Schmidt ML, Donninger H, Clark GJ (2017) The role of the NORE1A tumor suppressor in oncogene-induced senescence. Cancer Lett 400:30–36. https://doi.org/10.1016/j.canlet.2017.04.030 Boehr DD, Nussinov R, Wright PE (2009) The role of dynamic conformational ensembles in biomolecular recognition. Nat Chem Biol 5:789–796. https://doi.org/10.1038/nchembio.232 Boriack-Sjodin PA, Margarit SM, Bar-Sagi D, Kuriyan J (1998) The structural basis of the activation of Ras by Sos. Nature 394:337–343. https://doi.org/10.1038/28548 Bruder JT, Heidecker G, Rapp UR (1992) Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. Genes Dev 6:545–556 Burke JE, Perisic O, Masson GR, Vadas O, Williams RL (2012) Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110 alpha (PIK3CA). Proc Natl Acad Sci U S A 109:15259–15264. https://doi.org/10.1073/pnas.1205508109 Castellano E, Downward J (2011) RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2:261–274. https://doi.org/10.1177/1947601911408079 Chang LC et al (2014) Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA. BMC Gastroenterol 14(221). https://doi.org/10.1186/s12876-014-0221-y Chardin P, Camonis JH, Gale NW, van Aelst L, Schlessinger J, Wigler MH, Bar-Sagi D (1993) Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science 260:1338–1343 Chaudhuri P, Rosenbaum MA, Sinharoy P, Damron DS, Birnbaumer L, Graham LM (2016) Membrane translocation of TRPC6 channels and endothelial migration are regulated by calmodulin and PI3 kinase activation. Proc Natl Acad Sci U S A 113:2110–2115. https://doi.org/10.1073/pnas.1600371113 Chavan TS et al (2015) High-affinity interaction of the K-Ras4B hypervariable region with the Ras active site. Biophys J 109:2602–2613. https://doi.org/10.1016/j.bpj.2015.09.034 Cherfils J, Chardin P (1999) GEFs: structural basis for their activation of small GTP-binding proteins. Trends Biochem Sci 24:306–311 Cherfils J, Zeghouf M (2013) Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol Rev 93:269–309. https://doi.org/10.1152/physrev.00003.2012 Choi BH, Chen C, Philips M, Dai W (2018) RAS GTPases are modified by SUMOylation. Oncotarget 9:4440–4450. https://doi.org/10.18632/oncotarget.23269 Choi S, Anderson RA (2016) IQGAP1 is a phosphoinositide effector and kinase scaffold. Adv Biol Regul 60:29–35. https://doi.org/10.1016/j.jbior.2015.10.004 Choi S, Hedman AC, Sayedyahossein S, Thapa N, Sacks DB, Anderson RA (2016) Agonist-stimulated phosphatidylinositol-3,4,5-trisphosphate generation by scaffolded phosphoinositide kinases. Nat Cell Biol 18:1324–1335. https://doi.org/10.1038/ncb3441 Chong H, Guan KL (2003) Regulation of Raf through phosphorylation and N terminus-C terminus interaction. J Biol Chem 278:36269–36276. https://doi.org/10.1074/jbc.M212803200 Chong H, Lee J, Guan KL (2001) Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J 20:3716–3727. https://doi.org/10.1093/emboj/20.14.3716 Chuang E, Barnard D, Hettich L, Zhang XF, Avruch J, Marshall MS (1994) Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues. Mol Cell Biol 14:5318–5325 Cook SJ, McCormick F (1993) Inhibition by cAMP of Ras-dependent activation of Raf. Science 262:1069–1072 Crews CM, Erikson RL (1993) Extracellular signals and reversible protein phosphorylation: what to Mek of it all. Cell 74:215–217 Cutler RE Jr, Stephens RM, Saracino MR, Morrison DK (1998) Autoregulation of the Raf-1 serine/threonine kinase. Proc Natl Acad Sci U S A 95:9214–9219 Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, Peterson JR (2008) An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 15:322–331. https://doi.org/10.1016/j.chembiol.2008.03.005 del Sol A, Tsai CJ, Ma B, Nussinov R (2009) The origin of allosteric functional modulation: multiple pre-existing pathways. Structure 17:1042–1050. https://doi.org/10.1016/j.str.2009.06.008 Dhillon AS, Meikle S, Yazici Z, Eulitz M, Kolch W (2002a) Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J 21:64–71 Dhillon AS, Pollock C, Steen H, Shaw PE, Mischak H, Kolch W (2002b) Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol 22:3237–3246 Donninger H, Schmidt ML, Mezzanotte J, Barnoud T, Clark GJ (2016) Ras signaling through RASSF proteins. Semin Cell Dev Biol 58:86–95. https://doi.org/10.1016/j.semcdb.2016.06.007 Dumaz N, Marais R (2003) Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J Biol Chem 278:29819–29823. https://doi.org/10.1074/jbc.C300182200 Fallahi E, O’Driscoll NA, Matallanas D (2016) The MST/Hippo pathway and cell death: a non-canonical affair. Genes (Basel) 7:28. https://doi.org/10.3390/genes7060028 Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11:507–517 Fetics SK, Guterres H, Kearney BM, Buhrman G, Ma B, Nussinov R, Mattos C (2015) Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. Structure 23:505–516. https://doi.org/10.1016/j.str.2014.12.017 Francis SH, Poteet-Smith C, Busch JL, Richie-Jannetta R, Corbin JD (2002) Mechanisms of autoinhibition in cyclic nucleotide-dependent protein kinases. Front Biosci 7:d580–d592 Freedman TS, Sondermann H, Friedland GD, Kortemme T, Bar-Sagi D, Marqusee S, Kuriyan J (2006) A Ras-induced conformational switch in the Ras activator Son of Sevenless. Proc Natl Acad Sci U S A 103:16692–16697. https://doi.org/10.1073/pnas.0608127103 Freeman AK, Ritt DA, Morrison DK (2013) Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell 49:751–758. https://doi.org/10.1016/j.molcel.2012.12.018 Fukui M, Yamamoto T, Kawai S, Mitsunobu F, Toyoshima K (1987) Molecular cloning and characterization of an activated human c-raf-1 gene. Mol Cell Biol 7:1776–1781 Gabelli S et al (2014) Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects. Biophys Rev 6:89–95. https://doi.org/10.1007/s12551-013-0131-1 Goldfinger LE, Michael JV (2017) Regulation of Ras signaling and function by plasma membrane microdomains. Biosci Trends 11:23–40. https://doi.org/10.5582/bst.2016.01220 Gorfe AA, Hanzal-Bayer M, Abankwa D, Hancock JF, McCammon JA (2007) Structure and dynamics of the full-length lipid-modified H-Ras protein in a 1,2-dimyristoylglycero-3-phosphocholine bilayer. J Med Chem 50:674–684. https://doi.org/10.1021/jm061053f Gupta S et al (2007) Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 129:957–968. https://doi.org/10.1016/j.cell.2007.03.051 Gureasko J, Kuchment O, Makino DL, Sondermann H, Bar-Sagi D, Kuriyan J (2010) Role of the histone domain in the autoinhibition and activation of the Ras activator Son of Sevenless. Proc Natl Acad Sci U S A 107:3430–3435. https://doi.org/10.1073/pnas.0913915107 Hamad NM et al (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 16:2045–2057. https://doi.org/10.1101/gad.993902 Hatzivassiliou G et al (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431–435. https://doi.org/10.1038/nature08833 Hedman AC, Smith JM, Sacks DB (2015) The biology of IQGAP proteins: beyond the cytoskeleton. EMBO Rep 16:427–446. https://doi.org/10.15252/embr.201439834 Heidecker G et al (1990) Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol 10:2503–2512 Herrmann C, Horn G, Spaargaren M, Wittinghofer A (1996) Differential interaction of the ras family GTP-binding proteins H-Ras, Rap1A, and R-Ras with the putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor. J Biol Chem 271:6794–6800 Herrmann C, Martin GA, Wittinghofer A (1995) Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J Biol Chem 270:2901–2905 Hu J et al (2013) Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 154:1036–1046. https://doi.org/10.1016/j.cell.2013.07.046 Huang CH et al (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318:1744–1748. https://doi.org/10.1126/science.1150799 Hwang E et al (2014) Structural basis of the heterodimerization of the MST and RASSF SARAH domains in the hippo signalling pathway. Acta Crystallogr D Biol Crystallogr 70:1944–1953. https://doi.org/10.1107/S139900471400947X Improta-Brears T, Ghosh S, Bell RM (1999) Mutational analysis of Raf-1 cysteine rich domain: requirement for a cluster of basic aminoacids for interaction with phosphatidylserine. Mol Cell Biochem 198:171–178 Ishikawa F, Sakai R, Ochiai M, Takaku F, Sugimura T, Nagao M (1988) Identification of a transforming activity suppressing sequence in the c-raf oncogene. Oncogene 3:653–658 Ishikawa F, Takaku F, Hayashi K, Nagao M, Sugimura T (1986) Activation of rat c-raf during transfection of hepatocellular carcinoma DNA. Proc Natl Acad Sci U S A 83:3209–3212 Iwasa H, Hossain S, Hata Y (2018) Tumor suppressor C-RASSF proteins. Cell Mol Life Sci 75:1773–1787. https://doi.org/10.1007/s00018-018-2756-5 Jambrina PG, Bohuszewicz O, Buchete NV, Kolch W, Rosta E (2014) Molecular mechanisms of asymmetric RAF dimer activation. Biochem Soc Trans 42:784–790. https://doi.org/10.1042/BST20140025 Jambrina PG et al (2016) Phosphorylation of RAF kinase dimers drives conformational changes that facilitate transactivation. Angew Chem Int Ed Engl 55:983–986. https://doi.org/10.1002/anie.201509272 Jang H et al (2015) Mechanisms of membrane binding of small GTPase K-Ras4B farnesylated hypervariable region. J Biol Chem 290:9465–9477. https://doi.org/10.1074/jbc.M114.620724 Jang H, Banerjee A, Chavan T, Gaponenko V, Nussinov R (2017) Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction. J Biol Chem 292:12544–12559. https://doi.org/10.1074/jbc.M117.785063 Jang H, Banerjee A, Chavan TS, Lu S, Zhang J, Gaponenko V, Nussinov R (2016) The higher level of complexity of K-Ras4B activation at the membrane. FASEB J 30:1643–1655. https://doi.org/10.1096/fj.15-279091 Jarvis LM (2011) Pi3k at the clinical crossroads. Chemical & Engineering News 89:15–19 Jaumot M, Hancock JF (2001) Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions. Oncogene 20:3949–3958. https://doi.org/10.1038/sj.onc.1204526 Jin T, Lavoie H, Sahmi M, David M, Hilt C, Hammell A, Therrien M (2017) RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition. Nat Commun 8(1211). https://doi.org/10.1038/s41467-017-01274-0 Joyal JL, Burks DJ, Pons S, Matter WF, Vlahos CJ, White MF, Sacks DB (1997) Calmodulin activates phosphatidylinositol 3-kinase. J Biol Chem 272:28183–28186 Joyal JL, Crimmins DL, Thoma RS, Sacks DB (1996) Identification of insulin-stimulated phosphorylation sites on calmodulin. Biochemistry 35:6267–6275. https://doi.org/10.1021/bi9600198 Karasarides M, Anand-Apte B, Wolfman A (2001) A direct interaction between oncogenic ha-Ras and phosphatidylinositol 3-kinase is not required for Ha-Ras-dependent transformation of epithelial cells. J Biol Chem 276:39755–39764. https://doi.org/10.1074/jbc.M102401200 Kim AS, Kakalis LT, Abdul-Manan N, Liu GA, Rosen MK (2000) Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 404:151–158. https://doi.org/10.1038/35004513 Kodaki T, Woscholski R, Hallberg B, Rodriguez-Viciana P, Downward J, Parker PJ (1994) The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol 4:798–806 Kohler M et al (2016) Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants. EMBO J 35:143–161. https://doi.org/10.15252/embj.201592097 Kumar S, Ma B, Tsai CJ, Sinha N, Nussinov R (2000) Folding and binding cascades: dynamic landscapes and population shifts. Protein Sci 9:10–19. https://doi.org/10.1110/ps.9.1.10 Lavoie H et al (2018) MEK drives BRAF activation through allosteric control of KSR proteins. Nature 554:549–553. https://doi.org/10.1038/nature25478 Lavoie H, Therrien M (2015) Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol 16:281–298. https://doi.org/10.1038/nrm3979 Lavoie H et al (2013) Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol 9:428–436. https://doi.org/10.1038/nchembio.1257 Lepri F et al (2011) SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum Mutat 32:760–772. https://doi.org/10.1002/humu.21492 Li S, Jang H, Zhang J, Nussinov R (2018a) Raf-1 cysteine-rich domain increases the affinity of K-Ras/Raf at the membrane, promoting MAPK signaling. Structure 26:513–525. https://doi.org/10.1016/j.str.2018.01.011 Li Z, Sacks DB (2003) Elucidation of the interaction of calmodulin with the IQ motifs of IQGAP1. J Biol Chem 278:4347–4352. https://doi.org/10.1074/jbc.M208579200 Li ZL, Buck M (2017) Computational modeling reveals that signaling lipids modulate the orientation of K-Ras4A at the membrane reflecting protein topology. Structure 25:679–689 e672. https://doi.org/10.1016/j.str.2017.02.007 Li ZL, Prakash P, Buck M (2018b) A “tug of war” maintains a dynamic protein-membrane complex: molecular dynamics simulations of C-Raf RBD-CRD bound to K-Ras4B at an anionic membrane. ACS Cent Sci 4:298–305. https://doi.org/10.1021/acscentsci.7b00593 Liao J, Planchon SM, Wolfman JC, Wolfman A (2006) Growth factor-dependent AKT activation and cell migration requires the function of c-K(B)-Ras versus other cellular ras isoforms. J Biol Chem 281:29730–29738. https://doi.org/10.1074/jbc.M600668200 Liao TJ, Jang H, Fushman D, Nussinov R (2018) Allosteric KRas4B can modulate SOS1 fast and slow Ras activation cycles. Biophys J. https://doi.org/10.1016/j.bpj.2018.07.016 Liao TJ, Jang H, Tsai CJ, Fushman D, Nussinov R (2017) The dynamic mechanism of RASSF5 and MST kinase activation by Ras. Phys Chem Chem Phys 19:6470–6480. https://doi.org/10.1039/c6cp08596b Liao TJ, Tsai CJ, Jang H, Fushman D, Nussinov R (2016) RASSF5: an MST activator and tumor suppressor in vivo but opposite in vitro. Curr Opin Struct Biol 41:217–224. https://doi.org/10.1016/j.sbi.2016.09.001 Light Y, Paterson H, Marais R (2002) 14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity. Mol Cell Biol 22:4984–4996 Linnemann T, Kiel C, Herter P, Herrmann C (2002) The activation of RalGDS can be achieved independently of its Ras binding domain. Implications of an activation mechanism in Ras effector specificity and signal distribution. J Biol Chem 277:7831–7837. https://doi.org/10.1074/jbc.M110800200 Liu J, Nussinov R (2016) Allostery: an overview of its history, concepts, methods, and applications. PLoS Comput Biol 12:e1004966. https://doi.org/10.1371/journal.pcbi.1004966 Liu J, Nussinov R (2017) Energetic redistribution in allostery to execute protein function. Proc Natl Acad Sci U S A 114:7480–7482. https://doi.org/10.1073/pnas.1709071114 Lommerse PH, Snaar-Jagalska BE, Spaink HP, Schmidt T (2005) Single-molecule diffusion measurements of H-Ras at the plasma membrane of live cells reveal microdomain localization upon activation. J Cell Sci 118:1799–1809. https://doi.org/10.1242/jcs.02300 Ma B, Kumar S, Tsai CJ, Nussinov R (1999) Folding funnels and binding mechanisms. Protein Eng 12:713–720 Ma B, Tsai CJ, Haliloglu T, Nussinov R (2011) Dynamic allostery: linkers are not merely flexible. Structure 19:907–917. https://doi.org/10.1016/j.str.2011.06.002 Makbul C, Constantinescu Aruxandei D, Hofmann E, Schwarz D, Wolf E, Herrmann C (2013) Structural and thermodynamic characterization of Nore1-SARAH: a small, helical module important in signal transduction networks. Biochemistry 52:1045–1054. https://doi.org/10.1021/bi3014642 Mandelker D et al (2009) A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane. Proc Natl Acad Sci U S A 106:16996–17001. https://doi.org/10.1073/pnas.0908444106 Margarit SM et al (2003) Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell 112:685–695 Martins AJ et al (2017) Environment tunes propagation of cell-to-cell variation in the human macrophage gene network. Cell Syst 4 e312:379–392. https://doi.org/10.1016/j.cels.2017.03.002 Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R (1999) Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 18:2137–2148. https://doi.org/10.1093/emboj/18.8.2137 Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A, Kolch W (2011) Raf family kinases: old dogs have learned new tricks. Genes Cancer 2:232–260. https://doi.org/10.1177/1947601911407323 Mazhab-Jafari MT et al (2015) Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site. Proc Natl Acad Sci U S A 112:6625–6630. https://doi.org/10.1073/pnas.1419895112 Michael JV, Wurtzel JG, Goldfinger LE (2016) Inhibition of Galectin-1 sensitizes HRAS-driven tumor growth to rapamycin treatment. Anticancer Res 36:5053–5061. https://doi.org/10.21873/anticanres.11074 Michaud NR, Fabian JR, Mathes KD, Morrison DK (1995) 14-3-3 is not essential for Raf-1 function: identification of Raf-1 proteins that are biologically activated in a 14-3-3- and Ras-independent manner. Mol Cell Biol 15:3390–3397 Miled N et al (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317:239–242. https://doi.org/10.1126/science.1135394 Molders H, Defesche J, Muller D, Bonner TI, Rapp UR, Muller R (1985) Integration of transfected LTR sequences into the c-raf proto-oncogene: activation by promoter insertion. EMBO J 4:693–698 Molzan M, Ottmann C (2012) Synergistic binding of the phosphorylated S233- and S259-binding sites of C-RAF to one 14-3-3zeta dimer. J Mol Biol 423:486–495. https://doi.org/10.1016/j.jmb.2012.08.009 Morrison DK, Heidecker G, Rapp UR, Copeland TD (1993) Identification of the major phosphorylation sites of the Raf-1 kinase. J Biol Chem 268:17309–17316 Mott HR, Carpenter JW, Zhong S, Ghosh S, Bell RM, Campbell SL (1996) The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site. Proc Natl Acad Sci U S A 93:8312–8317 Muslin AJ, Tanner JW, Allen PM, Shaw AS (1996) Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84:889–897 Nakhaeizadeh H, Amin E, Nakhaei-Rad S, Dvorsky R, Ahmadian MR (2016) The RAS-effector Interface: isoform-specific differences in the effector binding regions. PLoS One 11:e0167145. https://doi.org/10.1371/journal.pone.0167145 Nussinov R (2016) Introduction to protein ensembles and allostery. Chem Rev 116:6263–6266. https://doi.org/10.1021/acs.chemrev.6b00283 Nussinov R, Jang H, Tsai CJ, Liao TJ, Li S, Fushman D, Zhang J (2017a) Intrinsic protein disorder in oncogenic KRAS signaling. Cell Mol Life Sci 74:3245–3261. https://doi.org/10.1007/s00018-017-2564-3 Nussinov R, Ma B, Tsai CJ (2013a) A broad view of scaffolding suggests that scaffolding proteins can actively control regulation and signaling of multienzyme complexes through allostery. Biochim Biophys Acta 1834:820–829. https://doi.org/10.1016/j.bbapap.2012.12.014 Nussinov R, Ma B, Tsai CJ, Csermely P (2013b) Allosteric conformational barcodes direct signaling in the cell. Structure 21:1509–1521. https://doi.org/10.1016/j.str.2013.06.002 Nussinov R, Muratcioglu S, Tsai CJ, Jang H, Gursoy A, Keskin O (2015a) The key role of calmodulin in KRAS-driven adenocarcinomas. Mol Cancer Res 13:1265–1273. https://doi.org/10.1158/1541-7786.MCR-15-0165 Nussinov R, Muratcioglu S, Tsai CJ, Jang H, Gursoy A, Keskin O (2016a) K-Ras4B/calmodulin/PI3Kalpha: a promising new adenocarcinoma-specific drug target? Expert Opin Ther Targets 20:831–842. https://doi.org/10.1517/14728222.2016.1135131 Nussinov R, Tsai CJ (2015) ‘Latent drivers’ expand the cancer mutational landscape. Curr Opin Struct Biol 32:25–32. https://doi.org/10.1016/j.sbi.2015.01.004 Nussinov R, Tsai CJ, Csermely P (2011) Allo-network drugs: harnessing allostery in cellular networks. Trends Pharmacol Sci 32:686–693. https://doi.org/10.1016/j.tips.2011.08.004 Nussinov R, Tsai CJ, Jang H (2016b) Independent and core pathways in oncogenic KRAS signaling. Expert Rev Proteomics 13:711–716. https://doi.org/10.1080/14789450.2016.1209417 Nussinov R, Tsai CJ, Jang H (2018a) Is nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant? Semin Cancer Biol:DOI. https://doi.org/10.1016/j.semcancer.2018.1001.1002 Nussinov R, Tsai CJ, Jang H (2018b) Oncogenic KRas mobility in the membrane and signaling response. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2018.1002.1009 Nussinov R, Tsai CJ, Jang H (2018c) Oncogenic Ras isoforms signaling specificity at the membrane. Cancer Res 78:593–602. https://doi.org/10.1158/0008-5472.CAN-17-2727 Nussinov R, Tsai CJ, Jang H, Korcsmaros T, Csermely P (2016c) Oncogenic KRAS signaling and YAP1/beta-catenin: similar cell cycle control in tumor initiation. Semin Cell Dev Biol 58:79–85. https://doi.org/10.1016/j.semcdb.2016.04.001 Nussinov R, Tsai CJ, Ma B (2013c) The underappreciated role of allostery in the cellular network. Annu Rev Biophys 42:169–189. https://doi.org/10.1146/annurev-biophys-083012-130257 Nussinov R, Tsai CJ, Muratcioglu S, Jang H, Gursoy A, Keskin O (2015b) Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation. Expert Rev Proteomics 12:669–682. https://doi.org/10.1586/14789450.2015.1100079 Nussinov R, Tsai CJ, Xin F, Radivojac P (2012) Allosteric post-translational modification codes. Trends Biochem Sci 37:447–455. https://doi.org/10.1016/j.tibs.2012.07.001 Nussinov R et al (2017b) Calmodulin and PI3K signaling in KRAS cancers. Trends Cancer 3:214–224. https://doi.org/10.1016/j.trecan.2017.01.007 Nussinov R, Wolynes PG (2014) A second molecular biology revolution? The energy landscapes of biomolecular function. Phys Chem Chem Phys 16:6321–6322. https://doi.org/10.1039/c4cp90027h Nussinov R, Zhang M, Tsai CJ, Jang H (2018d) Calmodulin and IQGAP1 activation of PI3Kalpha and Akt in KRAS, HRAS and NRAS-driven cancers. Biochim Biophys Acta 1864:2304–2314. https://doi.org/10.1016/j.bbadis.2017.10.032 Ory S, Zhou M, Conrads TP, Veenstra TD, Morrison DK (2003) Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr Biol 13:1356–1364 Owonikoko TK, Khuri FR (2013) Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book:DOI. https://doi.org/10.1200/EdBook_AM.2013.1233.e1395 Ozdemir ES, Jang H, Gursoy A, Keskin O, Li Z, Sacks DB, Nussinov R (2018) Unraveling the molecular mechanism of interactions of the Rho GTPases Cdc42 and Rac1 with the scaffolding protein IQGAP2. J Biol Chem 293:3685–3699. https://doi.org/10.1074/jbc.RA117.001596 Pacold ME et al (2000) Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103:931–943 Panchal SC, Kaiser DA, Torres E, Pollard TD, Rosen MK (2003) A conserved amphipathic helix in WASP/Scar proteins is essential for activation of Arp2/3 complex. Nat Struct Biol 10:591–598. https://doi.org/10.1038/nsb952 Peterson JR, Bickford LC, Morgan D, Kim AS, Ouerfelli O, Kirschner MW, Rosen MK (2004) Chemical inhibition of N-WASP by stabilization of a native autoinhibited conformation. Nat Struct Mol Biol 11:747–755. https://doi.org/10.1038/nsmb796 Peterson JR, Golemis EA (2004) Autoinhibited proteins as promising drug targets. J Cell Biochem 93:68–73. https://doi.org/10.1002/jcb.20184 Pierre S, Bats AS, Coumoul X (2011) Understanding SOS (Son of Sevenless). Biochem Pharmacol 82:1049–1056. https://doi.org/10.1016/j.bcp.2011.07.072 Pons-Tostivint E, Thibault B, Guillermet-Guibert J (2017) Targeting PI3K signaling in combination cancer therapy. Trends Cancer 3:454–469. https://doi.org/10.1016/j.trecan.2017.04.002 Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427–430. https://doi.org/10.1038/nature08902 Rabinovich GA (2005) Galectin-1 as a potential cancer target. Br J Cancer 92:1188–1192. https://doi.org/10.1038/sj.bjc.6602493 Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M (2009) A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461:542–545. https://doi.org/10.1038/nature08314 Ren JG, Li Z, Sacks DB (2008) IQGAP1 integrates Ca2+/calmodulin and B-Raf signaling. J Biol Chem 283:22972–22982. https://doi.org/10.1074/jbc.M804626200 Richter AM, Pfeifer GP, Dammann RH (2009) The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 1796:114–128. https://doi.org/10.1016/j.bbcan.2009.03.004 Rodriguez-Viciana P, Sabatier C, McCormick F (2004) Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 24:4943–4954. https://doi.org/10.1128/MCB.24.11.4943-4954.2004 Rodriguez-Viciana P et al (1997) Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457–467 Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J (1996) Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 15:2442–2451 Rojas JM, Oliva JL, Santos E (2011) Mammalian son of sevenless guanine nucleotide exchange factors: old concepts and new perspectives. Genes Cancer 2:298–305. https://doi.org/10.1177/1947601911408078 Romano D, Nguyen LK, Matallanas D, Halasz M, Doherty C, Kholodenko BN, Kolch W (2014) Protein interaction switches coordinate Raf-1 and MST2/hippo signalling. Nat Cell Biol 16:673–684. https://doi.org/10.1038/ncb2986 Rommel C et al (1999) Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286:1738–1741 Rommel C et al (1996) Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1. Oncogene 12:609–619 Rotblat B et al (2010) H-Ras nanocluster stability regulates the magnitude of MAPK signal output. PLoS One 5:e11991. https://doi.org/10.1371/journal.pone.0011991 Rusanescu G, Gotoh T, Tian X, Feig LA (2001) Regulation of Ras signaling specificity by protein kinase C. Mol Cell Biol 21:2650–2658. https://doi.org/10.1128/MCB.21.8.2650-2658.2001 Sanchez-Sanz G et al (2016) SARAH domain-mediated MST2-RASSF dimeric interactions. PLoS Comput Biol 12:e1005051. https://doi.org/10.1371/journal.pcbi.1005051 Schlessinger J (2003) Signal transduction. Autoinhibition control. Science 300:750–752. https://doi.org/10.1126/science.1082024 Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295–308. https://doi.org/10.1038/nrc2109 Schultz AM, Copeland T, Oroszlan S, Rapp UR (1988) Identification and characterization of c-raf phosphoproteins in transformed murine cells. Oncogene 2:187–193 Simicek M et al (2013) The deubiquitylase USP33 discriminates between RALB functions in autophagy and innate immune response. Nat Cell Biol 15:1220–1230. https://doi.org/10.1038/ncb2847 Smith JM, Hedman AC, Sacks DB (2015) IQGAPs choreograph cellular signaling from the membrane to the nucleus. Trends Cell Biol 25:171–184. https://doi.org/10.1016/j.tcb.2014.12.005 Stanishneva-Konovalova TB, Kelley CF, Eskin TL, Messelaar EM, Wasserman SA, Sokolova OS, Rodal AA (2016) Coordinated autoinhibition of F-BAR domain membrane binding and WASp activation by nervous wreck. Proc Natl Acad Sci U S A 113:E5552–E5561. https://doi.org/10.1073/pnas.1524412113 Stanton VP Jr, Cooper GM (1987) Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol Cell Biol 7:1171–1179 Stanton VP Jr, Nichols DW, Laudano AP, Cooper GM (1989) Definition of the human raf amino-terminal regulatory region by deletion mutagenesis. Mol Cell Biol 9:639–647 Stephens L, Williams R, Hawkins P (2005) Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol 5:357–365. https://doi.org/10.1016/j.coph.2005.03.002 Stieglitz B, Bee C, Schwarz D, Yildiz O, Moshnikova A, Khokhlatchev A, Herrmann C (2008) Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II. EMBO J 27:1995–2005. https://doi.org/10.1038/emboj.2008.125 Sydor JR, Engelhard M, Wittinghofer A, Goody RS, Herrmann C (1998) Transient kinetic studies on the interaction of Ras and the Ras-binding domain of c-Raf-1 reveal rapid equilibration of the complex. Biochemistry 37:14292–14299. https://doi.org/10.1021/bi980764f Tartaglia M et al (2007) Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39:75–79. https://doi.org/10.1038/ng1939 Terrell EM, Morrison DK (2018) Ras-mediated activation of the Raf family kinases. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a033746 Thapar R, Williams JG, Campbell SL (2004) NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation. J Mol Biol 343:1391–1408. https://doi.org/10.1016/j.jmb.2004.08.106 Thevakumaran N, Lavoie H, Critton DA, Tebben A, Marinier A, Sicheri F, Therrien M (2015) Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nat Struct Mol Biol 22:37–43. https://doi.org/10.1038/nsmb.2924 Tran NH, Frost JA (2003) Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition. J Biol Chem 278:11221–11226. https://doi.org/10.1074/jbc.M210318200 Tran NH, Wu X, Frost JA (2005) B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J Biol Chem 280:16244–16253. https://doi.org/10.1074/jbc.M501185200 Travers T, Lopez CA, Van QN, Neale C, Tonelli M, Stephen AG, Gnanakaran S (2018) Molecular recognition of RAS/RAF complex at the membrane: role of RAF cysteine-rich domain. Sci Rep 8(8461). https://doi.org/10.1038/s41598-018-26832-4 Tsai CJ, Del Sol A, Nussinov R (2009) Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms. Mol BioSyst 5:207–216. https://doi.org/10.1039/b819720b Tsai CJ, Kumar S, Ma B, Nussinov R (1999a) Folding funnels, binding funnels, and protein function. Protein Sci 8:1181–1190. https://doi.org/10.1110/ps.8.6.1181 Tsai CJ, Ma B, Nussinov R (1999b) Folding and binding cascades: shifts in energy landscapes. Proc Natl Acad Sci U S A 96:9970–9972 Tsai CJ, Nussinov R (2014a) The free energy landscape in translational science: how can somatic mutations result in constitutive oncogenic activation? Phys Chem Chem Phys 16:6332–6341. https://doi.org/10.1039/c3cp54253j Tsai CJ, Nussinov R (2014b) A unified view of “how allostery works”. PLoS Comput Biol 10:e1003394. https://doi.org/10.1371/journal.pcbi.1003394 Tu H, Wigler M (1999) Genetic evidence for Pak1 autoinhibition and its release by Cdc42. Mol Cell Biol 19:602–611 Tzivion G, Luo Z, Avruch J (1998) A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 394:88–92. https://doi.org/10.1038/27938 Vadas O, Burke JE, Zhang X, Berndt A, Williams RL (2011) Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal 4:re2. https://doi.org/10.1126/scisignal.2002165 Vandal G, Geiling B, Dankort D (2014) Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation. PLoS One 9:e84745. https://doi.org/10.1371/journal.pone.0084745 Vanhaesebroeck B et al (2001) Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70:535–602. https://doi.org/10.1146/annurev.biochem.70.1.535 Villalonga P et al (2001) Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol Cell Biol 21:7345–7354. https://doi.org/10.1128/MCB.21.21.7345-7354.2001 Vo U, Vajpai N, Flavell L, Bobby R, Breeze AL, Embrey KJ, Golovanov AP (2016) Monitoring Ras interactions with the nucleotide exchange factor Son of Sevenless (Sos) using site-specific NMR reporter signals and intrinsic fluorescence. J Biol Chem 291:1703–1718. https://doi.org/10.1074/jbc.M115.691238 Wan L et al (2017) The APC/C E3 ligase complex activator FZR1 restricts BRAF oncogenic function. Cancer Discov 7:424–441. https://doi.org/10.1158/2159-8290.CD-16-0647 Wan PT et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867 Wang G et al (2018) Interaction of calmodulin with the cSH2 domain of the p85 regulatory subunit. Biochemistry 57:1917–1928. https://doi.org/10.1021/acs.biochem.7b01130 Wei G, Xi W, Nussinov R, Ma B (2016) Protein ensembles: how does nature harness thermodynamic fluctuations for life? The diverse functional roles of conformational ensembles in the cell. Chem Rev 116:6516–6551. https://doi.org/10.1021/acs.chemrev.5b00562 Weise K et al (2011) Membrane-mediated induction and sorting of K-Ras microdomain signaling platforms. J Am Chem Soc 133:880–887. https://doi.org/10.1021/ja107532q White CD, Brown MD, Sacks DB (2009) IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett 583:1817–1824. https://doi.org/10.1016/j.febslet.2009.05.007 Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW (1993) Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science 262:1065–1069 Xu Y, Li N, Xiang R, Sun P (2014) Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem Sci 39:268–276. https://doi.org/10.1016/j.tibs.2014.04.004 Zhang BH, Guan KL (2000) Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 19:5429–5439. https://doi.org/10.1093/emboj/19.20.5429 Zhang BH, Guan KL (2001) Regulation of the Raf kinase by phosphorylation. Exp Lung Res 27:269–295 Zhang C et al (2015) RAF inhibitors that evade paradoxical MAPK pathway activation. Nature 526:583–586. https://doi.org/10.1038/nature14982 Zhang L et al (2018a) Ras and Rap signal bidirectional synaptic plasticity via distinct subcellular microdomains. Neuron 98 e784:783–800. https://doi.org/10.1016/j.neuron.2018.03.049 Zhang M, Jang H, Gaponenko V, Nussinov R (2017) Phosphorylated calmodulin promotes PI3K activation by binding to the SH2 domains. Biophys J 113:1956–1967. https://doi.org/10.1016/j.bpj.2017.09.008 Zhang M et al (2018b) Calmodulin (CaM) activates PI3Kalpha by targeting the “soft” CaM-binding motifs in both the nSH2 and cSH2 domains of p85alpha. J Phys Chem B. https://doi.org/10.1021/acs.jpcb.8b05982 Zhao L, Vogt PK (2008a) Class IPI3K in oncogenic cellular transformation. Oncogene 27:5486–5496. https://doi.org/10.1038/onc.2008.244 Zhao L, Vogt PK (2008b) Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 105:2652–2657. https://doi.org/10.1073/pnas.0712169105 Zhao L, Vogt PK (2010) Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9:596–600. https://doi.org/10.4161/cc.9.3.10599 Zimmermann S, Moelling K (1999) Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286:1741–1744